Treating intraocular inflammatory disease in the 21st century

Archives of Ophthalmology

Volumn 123, Issue 7, 2005, Pages 1000-1001

  Nussenblatt, Robert ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; EYE DISEASE; EYE INFLAMMATION; HUMAN; IMMUNE SYSTEM; MEDICAL LITERATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; AUTOIMMUNE DISEASE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NOTE; SAFETY; TREATMENT OUTCOME;

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; SAFETY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 22844446602     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.7.1000     Document Type: Editorial

References (2)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491-500.
2. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for patients with refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-912.